Biotechs seek treasure in pharma castoff, antibiotics

Antibiotics lack the revenue luster to keep pharma engaged, and only three have been approved by the FDA since 2006. But the niche looks good to some biotechs. "A smaller, more manageable product with revenue under $1 billion is fine for a biotech company," Needham & Co. analyst Alan Carr tells Bloomberg. Story